Figure 2.

Effect of empagliflozin (panel A) and dapagliflozin (panel B) on erythropoietin levels and iron status. Panel A (A) EPO levels in patients receiving empagliflozin 10 mg daily or placebo. (B) RBC indices, hemoglobin and hematocrit values, and iron status at baseline and after 6 months of empagliflozin or placebo. (C) Potential renal mechanisms for increased EPO with sodium-glucose cotransporter 2 (SGLT2) inhibition. Reprint permissions from Mazer et al.¹⁴Panel B: Plasma levels of erythropoietin and ferritin before and following 12 weeks of treatment with placebo or 10 mg daily of dapagliflozin. * = P < 0.05 compared to baseline in dapagliflozin group using ANOVA and paired t-test and #=P < 0.05 compared to placebo using two-way ANOVA and t-test. Adapted from J Clin Endocrinol Metab. 2020; 105:e1056-e1063.¹⁵